Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 March 2024 | Story Lacea Loader | Photo Stephen Collett
2024 Senate Conference
Keynote speakers during the UFS 2024 Senate Conference included, from the left: Prof Kristina Josefsson from University West, Sweden; Prof ‘Funmi Olonisakin from King’s College London, England; Prof Francis Petersen, Vice-Chancellor and Principal of the UFS and Chairperson of the Senate; and Prof Relebohile Moletsane from the University of KwaZulu-Natal.

The University of the Free State (UFS) presented its inaugural Senate Conference on the Bloemfontein Campus from 11 to 12 March 2024.

The conference, themed ‘Making Change through Engaged Scholarship’, initiated an important suite of conversations aligned with the UFS’ aspirations with Vision 130. The programme – which covered a wide range of topics by national and international speakers – included case studies of engaged scholarship from faculties, as well as breakaway sessions during which pertinent questions around engaged scholarship were discussed. A key element of the programme was the screening of a documentary film titled One Day, which accentuated the significance of engaged scholarship.

The organisation of the conference – both conceptually and logistically – was led by Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation at the UFS, supported by an organising committee consisting of various role players across the university.

Importance of engaged scholarship for universities

In his opening remarks, Prof Francis Petersen, Vice-Chancellor and Principal of the UFS, said that in the higher education sector, universities in South Africa, continentally, and globally are grappling with the key challenges of our time, including social justice, environmental degradation, and economic growth and job creation.

“We encounter these challenges in a global context that is increasingly volatile, and in which universities must constantly innovate and adapt in order to remain vibrant, relevant, and impactful. This is a time for higher education that is demanding, fraught, and disruptive. The challenges are many and complicated,” said Prof Petersen.

“Engaged scholarship is crucial for universities, particularly those in the Global South, as it fosters community collaboration, addresses local challenges, and promotes sustainable development,” he said.

Conference proceedings showcased of UFS’ involvement in engaged scholarship

On day 1, presentations included a discussion on ‘Engaged Scholarship in a Time of Geopolitical Contestation: An African Perspective’ by Prof ‘Funmi Olonisakin from King’s College London, England; and ‘Knowledge Products and Scholarship Engagement: The Way Forward for Universities’ by Prof Eugene Cloete from Stellenbosch University. The programme included a screening of a documentary film about engaged scholarship, titled One Day. Produced by Charlene Stanley from Storytown Productions, the film focused on the collapse of the tailings dam wall at the Jagersfontein Mine in September 2022 and the severe sludge damage to houses, property, and the environment. In particular, the film highlighted how the university’s interventions made a difference to the community. The day was concluded with presentations of engaged scholarship case studies from faculties, as well as group discussions.

Day 2 started off with a presentation by Prof Kristina Josefsson from University West, Sweden, on ‘Work-Integrated Learning and Engaged Scholarship – Meetings of Knowledge to Create Positive Change’, followed by a presentation on ‘Rurality, Community and Engaged Scholarship’ by Prof Relebohile Moletsane from the University of KwaZulu-Natal. As was done the previous day, presentations of engaged scholarship case studies from faculties and group discussions rounded off the day.

Some of the issues that have been identified and need to be taken further in order to embed engaged scholarship within the UFS, include the need to create a common understanding of engaged scholarship through careful interrogation of the terminology; the co-creation of knowledge, inter- and transdisciplinary approaches to solving problems; the impact of engaged scholarship on teaching, learning, and research interventions; and the sustainability of projects when the engaged scholars leave a community, and how to measure success or otherwise.

 

Programme

Click to view document UFS 2024 Senate Conference Programme

 

Documentary Film: One Day

 

Presentations

Click to view document ‘Knowledge Products and Scholarship Engagement: The Way Forward for Universities’ by Prof Eugene Cloete, Stellenbosch University.

Click to view document ‘Work-Integrated Learning and Engaged Scholarship – Meetings of Knowledge to Create Positive Change’ by Prof Kristina Josefsson from University West, Sweden.

Click to view document 'Rurality, Community and Engaged Scholarship’ by Prof Relebohile Moletsane from the University of KwaZulu-Natal.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept